Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
44 hedge funds and large institutions have $46.7M invested in Esperion Therapeutics in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0% more funds holding
Funds holding: 44 → 44 (0)
27% less capital invested
Capital invested by funds: $64.1M → $46.7M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$3.07M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.76M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$910K |
| 5 |
Millennium Management
New York
|
+$873K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.88M |
| 2 |
Morgan Stanley
New York
|
-$2.17M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.65M |
| 4 |
O
OrbiMed
New York
|
-$1.15M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
ESPR Hedge Fund Activity: Q4 2013 in Review
44 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2013, worth a combined $46.7M — down 27% from $64.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ESPR positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Pentwater Capital Management, adding an estimated $3.07M. The largest seller was Fidelity Investments, cutting an estimated $5.88M.
- 44 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $46.7M of Esperion Therapeutics stock for Q4 2013, down 27% quarter-over-quarter.
- 6 funds opened new Esperion Therapeutics positions in Q4 2013 and 5 closed out, a net change of +1 holder.
- The largest Esperion Therapeutics buyer in Q4 2013 was Pentwater Capital Management, an estimated $3.07M added.
- The largest Esperion Therapeutics seller in Q4 2013 was Fidelity Investments, an estimated $5.88M sold.
Based on aggregated 13F filings for Q4 2013.